Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Eli Lilly (LLY) has reportedly sent out cease-and-desist letters to compounding pharmacies and clinics that were providing copycat versions of its drugs Zepbound and Mounjaro.

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...

currently its main rival in the GLP-1 market with tirzepatide-based therapies Mounjaro and Zepbound. The two companies are in ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...